The Kingston Report

The Kingston Report

Is mRNA's Financial Forecasts Optimistic or Delusional? Stocks Continue to Plummet

PFE closed -4% down today, slashed 2023 sales by 13% and reduced EPS by $2 per share. MRNA drops more than 17% in value per a 5-day losing streak and more than 50% in value year-to-date.

Oct 18, 2023
∙ Paid
128
18
7
Share

October 18, 2023: Pfizer (PFE) closed today down another -4% ($1.41), dropping the stock by -43% (-$23.52) per share over the past 52-weeks.

On Friday October 23, 2023, Pfizer reported that;

  • Contract with the European Union were renegotiated

  • COVID-19 mRNA Injection and Paxlovid sales would miss 2023 forecasted sales by $12.5 billion

  • Overall 2023 forecaste…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Karen Kingston
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture